<DOC>
	<DOCNO>NCT00070564</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin , cyclophosphamide , paclitaxel , use different way stop tumor cell divide stop grow die . Combining one drug give surgery may kill remain tumor cell . It yet know combination chemotherapy regimen effective treating resect breast cancer . PURPOSE : This randomized phase III trial compare 2 different regimen combination chemotherapy see well work treat patient undergone surgery stage I , stage II , stage III breast cancer .</brief_summary>
	<brief_title>S0221 Adjuvant Doxorubicin , Cyclophosphamide , Paclitaxel Treating Patients With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare disease-free survival patient node-positive high-risk node-negative breast cancer treat 2 different schedule adjuvant doxorubicin , cyclophosphamide , paclitaxel . - Compare overall survival patient treat regimen . - Compare toxic effect regimens patient . - Correlate outcome putative prognostic marker patient treat regimen . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm ( arm V VI ) ( arm I-IV close 11/10/10 ) . - Arm I : ( close 11/10/10 ) Patients receive doxorubicin IV cyclophosphamide IV day 1 pegfilgrastim subcutaneously ( SC ) day 2 filgrastim ( G-CSF ) SC day 3-10 . Treatment repeat every 14 day 6 course . Beginning 2 week completion doxorubicin cyclophosphamide , patient receive paclitaxel IV 3 hour day 1 pegfilgrastim SC day 2 . Treatment repeat every 14 day 6 course . - Arm II : ( close 11/10/10 ) Patients receive doxorubicin IV day 1 , oral cyclophosphamide day 1-7 , G-CSF SC day 2-7 . Treatment repeat every 7 day 15 course . Beginning 2 week completion cyclophosphamide , patient receive paclitaxel pegfilgrastim arm I . - Arm III : ( close 11/10/10 ) Patients receive doxorubicin , cyclophosphamide , pegfilgrastim G-CSF arm I . Beginning 2 week completion doxorubicin cyclophosphamide , patient receive paclitaxel IV 1 hour day 1 . Treatment repeat every 7 day 12 course . - Arm IV : ( close 11/10/10 ) Patients receive doxorubicin , cyclophosphamide , G-CSF arm II . Beginning 2 week completion cyclophosphamide , patient receive paclitaxel arm III . - Arm V : Patients receive doxorubicin IV cyclophosphamide IV day 1 pegfilgrastim SC day 2 . Treatment repeat every 14 day 4 course . Patients receive doxorubicin IV cyclophosphamide IV day 1 pegfilgrastim SC day 2 . Treatment repeat every 14 day 6 course . Beginning 2 week completion doxorubicin cyclophosphamide , patient receive paclitaxel IV 3 hour day 1 pegfilgrastim SC day 2 . Treatment repeat every 14 day 6 course . - Arm VI : Patients receive doxorubicin , cyclophosphamide , pegfilgrastim arm V. Beginning 2 week completion doxorubicin cyclophosphamide , patient receive paclitaxel IV 1 hour day 1 . Treatment repeat every 7 day 12 course . In arm , treatment continue absence disease progression unacceptable toxicity . In arms patient HER2/neu-positive tumor also receive trastuzumab ( Herceptin® ) weekly every 3 week begin concurrently paclitaxel OR 3 month last dose paclitaxel continue 52 week . In arm , patient estrogen-receptor progesterone-receptor positive tumor receive hormonal therapy begin within 28 day completion adjuvant chemotherapy radiotherapy ( give ) . After finish study treatment patient follow every 6 month 5 year year 15 year . PROJECTED ACCRUAL : A total 3,250 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IIII invasive breast cancer Operable disease Stage I , II , IIIA , IIIC ( T13 , N3a ) No T4 tumor Highrisk disease , define 1 following : Tumor ≥ 2 cm great diameter ( include invasive intraductal component ) Patients nodal status N0+ ( i.e. , cluster tumor cell node great 0.2 mm ) consider node negative must primary tumor ≥ 2 cm size tumor ≥ 1 cm high risk feature Patients node negative basis sentinel node procedure few 6 axillary node remove eligible OR least 6 axillary intramammary node must negative Tumor ≥ 1 cm diameter meet 1 follow criterion : ERnegative PgRnegative ERpositive PgRpositive Genomic Health Recurrence Score ≥ 26 One axillary intramammary node involve metastatic breast cancer If one node involve , minimum 6 axillary intramammary node must examine histologically Patients N0 ( I+ ) disease consider node negative HER2/neupositive tumor ( 3+ immunohistochemical stain amplified fluorescence insitu hybridization ) allow Bilateral synchronous breast cancer diagnose within 1 month allow provide high TNM stage primary tumor meet eligibility criterion Prior modify radical mastectomy OR local excision tumor axillary lymph node dissection sentinel node resection require No 84 day since prior surgery primary tumor and/or axilla Final resection margin primary tumor must histologically negative invasive cancer ductal carcinoma situ Resection margin positive lobular carcinoma situ allow Hormone receptor status : Estrogen receptor status know Progesterone receptor status know PATIENT CHARACTERISTICS : Age 18 Sex Male female Menopausal status Not specify Performance status Zubrod 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,200/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great upper limit normal ( ULN ) Alkaline phosphatase great 2 time ULN SGOT SGPT great 2 time ULN Renal Creatinine great ULN Cardiovascular No congestive heart failure No active angina pectoris LVEF great equal low limit normal* MUGA echocardiogram NOTE : Patients age 60 OR history hypertension Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , situ cervical carcinoma , lobular carcinoma situ breast Prior invasive breast cancer ductal carcinoma situ allow diseasefree 5 year HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior cytotoxic chemotherapy breast cancer No prior chemotherapy anthracycline , anthracenedione , taxane Endocrine therapy Not specify Radiotherapy No prior radiotherapy malignancy At least 2 week since prior radiotherapy ductal carcinoma situ Surgery See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>HER2-positive breast cancer</keyword>
	<keyword>estrogen receptor-negative breast cancer</keyword>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>progesterone receptor-negative breast cancer</keyword>
	<keyword>progesterone receptor-positive breast cancer</keyword>
</DOC>